Catalog No.
DHD38503
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-nd
Clonality
Monoclonal
Target
Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P20273
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
90Y-DOTA-hLL2, 90Y-epratuzumab tetraxetan, AMG-412, 90Y-hLL2, hLL2, CAS: 205923-57-5
Clone ID
Epratuzumab
Epratuzumab for the treatment of systemic lupus erythematosus, PMID: 29542345
Epratuzumab for systemic lupus erythematosus, PMID: 23553783
Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives, PMID: 28088906
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus, PMID: 26212727
Epratuzumab: targeting B-cell malignancies through CD22, PMID: 14506198
Epratuzumab in the therapy of oncological and immunological diseases, PMID: 17069520
Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus, PMID: 25429203
Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases, PMID: 16918261
Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus, PMID: 25496332
Editorial: Epratuzumab: Reveille or Requiem? Teachable Moments for Lupus and Sjögren's Syndrome Clinical Trials, PMID: 29381841
Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials, PMID: 31316634
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials, PMID: 29381843
Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus, PMID: 21050432
Treatment of systemic lupus erythematosus with epratuzumab, PMID: 21219397
Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus, PMID: 28375452
Emerging B-Cell Therapies in Systemic Lupus Erythematosus, PMID: 33488082
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties, PMID: 14506197
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab, PMID: 16814387
Epratuzumab in non-Hodgkin's lymphomas, PMID: 15233905
Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies, PMID: 17530024
Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients, PMID: 26183319
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study, PMID: 16859536
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006, PMID: 24273022
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials, PMID: 27598855
Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab, PMID: 23821660
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review, PMID: 26654227
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab), PMID: 11842393
Technology evaluation: epratuzumab, Immunomedics/Amgen, PMID: 12772511
Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells, PMID: 25484043
Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study, PMID: 26382733
Systemic lupus erythematosus: Epratuzumab not effective in phase III trials, PMID: 27652506
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus, PMID: 16630358
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2, PMID: 25732247
Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor, PMID: 27125377
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study, PMID: 18669463
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study, PMID: 23313811
Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus, PMID: 29426575
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up, PMID: 23542611
Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls, PMID: 17673490
Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study, PMID: 26316325
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies, PMID: 22039078
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study, PMID: 26687796
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results, PMID: 15328168
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma, PMID: 25150258
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?, PMID: 14660727
Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma, PMID: 14506199
Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia, PMID: 28154086
Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22, PMID: 27352780
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab, PMID: 16033839
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma, PMID: 15102696
For research use only. Not for human or drug use.
